Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (1-10 of 221) with videos related to

Pageof 23
Sort By:
Archives of Pathology & Laboratory Medicine|April 7, 2018
Molecular Testing in Lung Cancer: Where to Draw the Line?Balazs Halmos
The Oncologist|April 12, 2014
The seventh doorBalazs Halmos
Translational Lung Cancer Research|February 2, 2019
Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?Brian Ko, Balazs Halmos
The Lancet. Oncology|September 15, 2022
Tissue-agnostic RET inhibition: can you trust your target?Angelica D'Aiello, Balazs Halmos
Annals of Translational Medicine|October 24, 2017
Emerging uses of biomarkers in lung cancer managementBalazs Halmos, Benjamin Levy
Translational Lung Cancer Research|March 14, 2022
How SOLID is the immune system's response to the deadly duo of lung cancer and SARS-CoV-2?Hiba Narvel, Balazs Halmos
Journal of Thoracic Disease|January 12, 2019
Expanding the gamut of circulating tumor DNA applicationsMeghan Kaumaya, Balazs Halmos
Annals of Translational Medicine|January 4, 2019
VEGF inhibitors in <i>EGFR</i>-mutated lung cancer: a never-ending story?Mariam Alexander, Balazs Halmos
British Journal of Cancer|September 5, 2022
Biomarker testing in cancer management- can one size fit all?Lynette M Sholl, Balazs Halmos
American Journal of Respiratory and Critical Care Medicine|August 2, 2011
Update in lung cancer and oncological disorders 2010Balazs Halmos, Charles A Powell
Pageof 23

Showing results (1-10 of 221) with videos related to

Sort By:
Pageof 23
Archives of Pathology & Laboratory Medicine|April 7, 2018
Molecular Testing in Lung Cancer: Where to Draw the Line?Balazs Halmos
The Oncologist|April 12, 2014
The seventh doorBalazs Halmos
Translational Lung Cancer Research|February 2, 2019
Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?Brian Ko, Balazs Halmos
The Lancet. Oncology|September 15, 2022
Tissue-agnostic RET inhibition: can you trust your target?Angelica D'Aiello, Balazs Halmos
Annals of Translational Medicine|October 24, 2017
Emerging uses of biomarkers in lung cancer managementBalazs Halmos, Benjamin Levy
Translational Lung Cancer Research|March 14, 2022
How SOLID is the immune system's response to the deadly duo of lung cancer and SARS-CoV-2?Hiba Narvel, Balazs Halmos
Journal of Thoracic Disease|January 12, 2019
Expanding the gamut of circulating tumor DNA applicationsMeghan Kaumaya, Balazs Halmos
Annals of Translational Medicine|January 4, 2019
VEGF inhibitors in <i>EGFR</i>-mutated lung cancer: a never-ending story?Mariam Alexander, Balazs Halmos
British Journal of Cancer|September 5, 2022
Biomarker testing in cancer management- can one size fit all?Lynette M Sholl, Balazs Halmos
American Journal of Respiratory and Critical Care Medicine|August 2, 2011
Update in lung cancer and oncological disorders 2010Balazs Halmos, Charles A Powell
Pageof 23